ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, addiction, chronic cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.…
Industry Peers
BiotechnologyKey Statistics
About Addex Therapeutics (SWX: ADXN)
›
Addex Therapeutics (SWX: ADXN) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 3 employees.
The shares were at 0.0246 CHF on 19 November 2026, down 60.2% over 52 weeks. Its 52-week range is 0.0180 CHF to 0.0690 CHF: the price is 64.3% below the high and 36.7% above the low.
Its market capitalisation is 5.17M CHF.
Addex Therapeutics reports return on equity of -141.2% and revenue down 72.7% year over year.
It holds more cash than debt, a net cash position of 689.83K CHF. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 23 November 2026.